Table 4.

First- and second-line combinations: Kaplan–Meier estimates for mOS

First- and second-line combinations
Number of patients	N 81	% 100	mOS Months; 95 % CI	Significance Log rank
Targeted therapy
Crossover	13	16	21.6 (18–46.8)	p = 0.78
Treatment beyond pd	12	15	33.6 (14.4–46.8)
None in first line	22	27	34.8 (22.8–48)
None in second line	20	25	27.6 (15.6–48)
None	14	17	28.8 (13.2–54)